Arylycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals

A compound of the formula I

• wherein:
• Ring A is (C3-C8)-cycloalkanediyl or (C3-C8)-cycloalkenediyl, wherein one or more carbon atoms of said (C3-C8)-cycloalkanediyl and (C3-C8)cycloalkenediyl groups are optionally replaced by oxygen atoms;
• R1, R2 are each independently H, F, Cl, Br, CF3, OCF3, (C1-C6)-alkyl, O—(C1-C6)-alkyl, SCF3, SF5, OCF2—CHF2, (C6-C10)-aryl, (C6-C10)-aryloxy, OH or NO2;
• or
• R1 and R2, taken together with the atoms of the phenyl, pyridine, 1-Hpyrrole, thiophene or furan rings to which they are attached, form a fused, partially saturated or unsaturated, bicyclic (C6-C10)-aryl or (C5—C11)-heteroaryl group;
• R3 is H, (β1-C6)-alkyl, (C3-C8)-cycloalkyl, (C1-C3)-alkyl-(C3-C8)-cycloalkyl, phenyl, (C1-C3)-alkyl-phenyl, (C5-C6)-heteroaryl, (C1-C3)-alkyl-(C5-C6)-heteroaryl or (C1-C3)-alkyl which is fully or partially substituted by F;
• W is CH or N, if o=1;
• W is O, S or NR9, if o=0;
• X is (C1-C6)-alkanediyl, wherein one or more carbon atoms of said (C1-C6)-alkanediyl group are optionally replaced by oxygen atoms;
• Y1 is O;
• Y2 is CR12R13, SO or SO2;
• n is 0, 1 or 2;
• R4 is H, F or (C1-C6)-alkyl;
• R5 is H, F or (C1-C6)-alkyl;
• R6 is H or (C1-C6)-alkyl;
• or is F if n is not 0;
• R7 is H, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O—(C1-C6)-alkyl, O—(C2-C6)-alkenyl, O—(C2-C6)-alkynyl, (C3-C8)-cycloalkyl, phenyl, (C5-C11)-heteroaryl, O—(C3-C8)-cycloalkyl or O-phenyl,
• wherein said (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O—(C1-C6)-alkyl, O—(C2-C6)-alkenyl, O—(C2-C6)-alkynyl, O—(C3-C8)-cycloalkyl and O-phenyl groups are optionally substituted by OH, NR10R11, O—(C1-C6)-alkyl, O—(C2-C6)-alkenyl, O—(C2-C6)-alkynyl, O—(C3-C8)-cycloalkyl, O-phenyl or O—(C5-C11)-heteroaryl, and
• said (C3-C8)-cycloalkyl, phenyl and (C5-C11)-heteroaryl groups are optionally substituted by OH, NR10R11, O—(C1-C6)-alkyl, O—(C2-C6)-alkenyl, O—(C2-C6)-alkynyl, O—(C3-C8)-cycloalkyl, O-phenyl, O—(C5-C11)-heteroaryl or (C1-C6)-alkyl,
• wherein said (C1-C6)-alkyl substituent is optionally substituted by F (fully or partially) or O—(C1-C6)-alkyl,
• wherein said O—(C1-C6)-alkyl substituent is optionally substituted by F (fully or partially), Cl, Br, I, OH, NR10R11, CO—(C1-C6)-alkyl, CO—(C6-C10)-aryl, CO—(C1-C6)-alkyl-(C6-C10)-aryl, CO—(C5-C11)-heteroaryl, C(O)—O—(C1-C6)-alkyl, C(O)—O—(C1-C6)-alkyl-(C6-C10)-aryl, C(O)—O—(C6-C10)-aryl, C(O)—O—(C5-C11)-heteroaryl, SO2-(C1-C6)-alkyl, SO2—(C1-C6)-alkyl-(C6-C10)-aryl, SO2-(C1-C6)-alkyl-SO2—(C1-C6)-alkyl, SO2—(C6-C10)-aryl, SO2—(C5-C11)-heteroaryl;
• or
• R6 and R7, together with the carbon atom to which they are attached, form a (C3-C8)-cycloalkyl group;
• R8 is H or (C1-C6)-alkyl;
• R9 is H or (C1-C6)-alkyl which is optionally substituted by phenyl;
• R10 is H or (C1-C6)-alkyl which is optionally substituted by phenyl;
• R11 is H or (C1-C6)-alkyl which is optionally substituted by phenyl;
• R12 is H or (C1-C6)-alkyl;
• R13 is H or (C1-C6)-alkyl;
• and pharmaceutically acceptable salts thereof.